About this event
Since their discovery viruses have been developed and used as biotherapeutics. Initially they were used as vaccines and more recently also as gene delivery systems and oncolytic agents. Their size, lifecycle and possibility to be genetically modified them, make viruses extremely suitable to modify or attack cells in vitro and in vivo. From a pharmaceutical point of view viruses are difficult to handle biologics. They are complex and often lack stability. Extensive formulation development is necessary to develop virus-based pharmaceuticals with acceptable shelf life and in-use stability.
In this on-demand webinar, our scientific advisor, Prof. Dr. Gideon Kersten addresses some critical aspects of formulation and characterization of virus-based biopharmaceuticals.
Coriolis Pharma is a globally operating contract research and development organization and one of the world leaders in formulation research and development of biopharmaceuticals including vaccines and ATMPs.